ArticleAntimicrobial agents and chemotherapy2019
Modified Mouse Model of Clostridioides difficile Infection as a Platform for Probiotic Efficacy Studies.
Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 13 citations in OpenAlex.
- Acidification-dependent suppression ofInfection and immunity · 2026Article
- Acidification-dependent suppression ofbioRxiv : the preprint server for biology · 2026Article
- Deoxycholate induces proline provision from Escherichia coli to enhance Clostridioides difficile virulence.The ISME journal · 2026Article
- Repurposing thioridazine as a potential CD2068 inhibitor to mitigate antibiotic resistance inComputational and structural biotechnology journal · 2025Article
- The state of play of rodent models for the study ofJournal of medical microbiology · 2024Review
- Reviewing theMicroorganisms · 2024Review
- Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model.The Journal of infectious diseases · 2023Article
- Article
- Therapeutic Effects of Bifidobacterium breve YH68 in Combination with Vancomycin and Metronidazole in a Primary Clostridioides difficile-Infected Mouse Model.Microbiology spectrum · 2022Article
- Evaluation of the therapeutic effect and dose-effect of Bifidobacterium breve on the primary Clostridioides difficile infected mice.Applied microbiology and biotechnology · 2021Article
- Strong Antimicrobial Effects of Xanthohumol and Beta-Acids from Hops againstAntibiotics (Basel, Switzerland) · 2021Article
- Outbreaks of Typhlocolitis Caused by Hypervirulent Group ST1Comparative medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Probiotics may represent a promising approach for reducing
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.